Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionNorges Bank
Latest Disclosed Ownership2,252,775 shares
Latest Disclosed Value $ 895,815,979
Norges Bank ownership in DUL / Alnylam Pharmaceuticals, Inc.

On February 10, 2026 - Norges Bank filed a 13F-HR form disclosing ownership of 2,252,775 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $761,212,672 USD as of December 31, 2025. The entity filed a previous 13F-HR on November 13, 2025 disclosing 0 shares of Alnylam Pharmaceuticals, Inc.. The current value of the position is $567,248,745 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-10 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,252,775 2,252,775 895,816 0.0958
2025-11-13 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 0 -2,032,680 -100.00 0 -100.00
2025-08-13 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,032,680 -103,344 -4.84 662,837 14.92 0.0827
2026-05-11 2025-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,136,024 -320,058 -13.03 576,769 -0.20 0.0810
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,456,082 80,547 3.39 577,941 -11.54 0.0758
2025-11-12 2024-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,375,535 78,754 3.43 653,343 17.06 0.0913
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,296,781 4,127 0.18 558,118 62.89 0.0834
2025-05-14 2024-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 2,292,654 252,856 12.40 342,637 -12.24 0.0541
2024-02-09 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 2,039,798 846,232 70.90 390,438 84.71 0.0682
2024-11-13 2023-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,193,566 490,212 69.70 211,381 58.22 0.0429
2024-08-14 2023-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 703,354 -818,058 -53.77 133,595 -56.17 0.0264
2024-05-15 2023-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,521,412 508,566 50.21 304,769 26.62 0.0667
2023-02-14 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 1,012,846 -205,338 -16.86 240,703 -1.28 0.0580
2023-11-13 2022-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,218,184 -66,593 -5.18 243,832 30.12 0.0648
2023-08-14 2022-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,284,777 -10,310 -0.80 187,385 -11.39 0.0484
2023-05-12 2022-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,295,087 25,896 2.04 211,475 -1.74 0.0461
2022-03-09 2021-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,269,191 274,303 27.57 215,229 14.58 0.0443
2022-11-14 2021-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 994,888 100,136 11.19 187,845 23.84 0.0416
2022-08-15 2021-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 894,752 -67,552 -7.02 151,678 11.64 0.0329
2022-05-09 2021-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 962,304 -76,684 -7.38 135,868 0.62 0.0311
2021-03-02 2020-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,038,988 -1,361 -0.13 135,037 -10.85 0.0315
2021-11-12 2020-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,040,349 138,030 15.30 151,475 13.34 0.0402
2021-08-13 2020-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 902,319 -85,446 -8.65 133,642 24.30 0.0385
2021-05-07 2020-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 987,765 -15,448 -1.54 107,518 -6.94 0.0383
2020-03-03 2019-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,003,213 -121,009 -10.76 115,540 27.80 0.0322
2020-11-13 2019-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,124,222 -14,780 -1.30 90,410 9.40 0.0277
2020-08-13 2019-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,139,002 -7,867 -0.69 82,645 -22.89 0.0255
2020-05-11 2019-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,146,869 -145,507 -11.26 107,175 13.74 0.0346
2019-03-04 2018-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,292,376 159,445 14.07 94,228 -4.97 0.0351
2019-12-02 2018-09-30 13F/A-3 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,132,931 314,695 38.46 99,154 23.04 0.0322
2019-12-02 2018-09-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,132,931 314,695 99,154 0.0322
2019-11-12 2018-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 1,132,931 314,695 99,154 0.0322
2019-08-12 2018-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 818,236 14,273 1.78 80,588 -15.84 0.0277
2019-05-15 2018-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 803,963 61,702 8.31 95,751 1.53 0.0346
2018-03-05 2017-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 742,261 187,242 33.74 94,304 44.62 0.0338
2018-11-13 2017-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 555,019 -189,396 -25.44 65,209 9.83 0.0247
2018-07-24 2017-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 744,415 100,000 15.52 59,374 79.77 0.0236
2018-05-11 2017-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 644,415 -20,248 -3.05 33,027 32.72 0.0136
2017-03-02 2016-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 664,663 116,894 21.34 24,885 -29.82 0.0109
2017-11-13 2016-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 547,769 87,008 18.88 35,461 38.69 0.0168
2017-08-09 2016-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 460,761 31,380 7.31 25,568 -5.14 0.0121
2017-05-10 2016-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 429,381 -168,776 -28.22 26,953 -52.14 0.0133
2016-04-18 2015-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 598,157 -66,811 -10.05 56,311 5.38 0.0280
2016-03-16 2015-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 598,157 0 56,311 0.0282
2016-11-14 2015-09-30 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 664,968 91,048 15.86 53,437 -22.33 0.0280
2016-08-12 2015-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 573,920 -21,374 -3.59 68,796 10.68 0.0344
2016-05-13 2015-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 595,294 42,633 7.71 62,160 15.95 0.0305
2015-03-19 2014-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 552,661 44,531 53,608 0.0273
2016-04-18 2014-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 552,661 44,531 8.76 53,608 35.08 0.0272
2015-11-12 2014-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 508,130 0 0.00 39,685 23.63 0.0215
2015-08-10 2014-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 508,130 114,239 29.00 32,099 21.38 0.0173
2015-05-12 2014-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 393,891 0 0.00 26,446 4.37 0.0149
2014-03-07 2013-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 393,891 15,873 25,339 0.0155
2014-03-20 2013-12-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 393,891 0 25,339 0.0149
2014-05-12 2013-12-31 13F/A-3 ALNYLAM PHARMACEUTICALS COM 02043Q107 393,891 15,873 4.20 25,339 4.72 0.0146
2014-11-14 2013-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 378,018 61,614 19.47 24,197 146.61 0.0141
2014-08-14 2013-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 316,404 109,391 52.84 9,812 94.49 0.0061
2014-04-04 2013-03-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 207,013 0 5,045 0.0033
2014-05-12 2013-03-31 13F/A-2 ALNYLAM PHARMACEUTICALS COM 02043Q107 207,013 0 0.00 5,045 29.69 0.0033
2013-11-14 2012-09-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 207,013 28,169 15.75 3,890 16.36 0.0026
2013-08-15 2012-06-30 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 178,844 178,844 3,343 0.0027
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.